oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

Summary

This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary efficacy of intratumoral injection of BS006 in patients with advanced solid tumors.

Timeline

Start

2023-12-19

Primary completion

2026-12-19

Completion

2026-12-19

Drugs

Indications